139 related articles for article (PubMed ID: 23460288)
21. Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis.
Simeoni M; Nicotera R; Colao M; Citraro ML; Pelagi E; Cerantonio A; Comi N; Coppolino G; Fuiano G
Int Urol Nephrol; 2016 Feb; 48(2):229-37. PubMed ID: 26438325
[TBL] [Abstract][Full Text] [Related]
22. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
23. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.
Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Małgorzewicz S; Rutkowski B
Am J Hypertens; 2012 Jun; 25(6):636-9. PubMed ID: 22357413
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin.
Lange S; Fraune C; Alenina N; Bader M; Danser AH; Frenay AR; van Goor H; Stahl R; Nguyen G; Schwedhelm E; Wenzel UO
J Hypertens; 2013 Apr; 31(4):713-9. PubMed ID: 23407438
[TBL] [Abstract][Full Text] [Related]
25. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
27. Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells.
Ferri N; Greco CM; Maiocchi G; Corsini A
J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):469-74. PubMed ID: 21628356
[TBL] [Abstract][Full Text] [Related]
28. Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease.
Serebruany VL; Malinin A; Barsness G; Vahabi J; Atar D
J Hum Hypertens; 2008 May; 22(5):303-10. PubMed ID: 18273042
[TBL] [Abstract][Full Text] [Related]
29. [Renin as a target of direct pharmacological block in arterial hypertension].
Mukhin NA; Fomin VV
Ter Arkh; 2009; 81(8):5-9. PubMed ID: 19799192
[TBL] [Abstract][Full Text] [Related]
30. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
31. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M
J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712
[TBL] [Abstract][Full Text] [Related]
32. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
Ayalasomayajula S; Yeh CM; Vaidyanathan S; Flannery B; Dieterich HA; Howard D; Bedigian MP; Dole WP
J Clin Pharmacol; 2008 Jul; 48(7):799-811. PubMed ID: 18490495
[TBL] [Abstract][Full Text] [Related]
33. The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes.
Savoia C; Arrabito E; Parente R; Sada L; Madaro L; Nicoletti C; Zezza L; Alonzo A; Rubattu S; Michelini S; Muller DN; Volpe M
Clin Sci (Lond); 2013 Aug; 125(4):183-9. PubMed ID: 23438195
[TBL] [Abstract][Full Text] [Related]
34. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
35. Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
Hypertension; 2011 Apr; 57(4):852-8. PubMed ID: 21321303
[TBL] [Abstract][Full Text] [Related]
36. How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?
Jagadeesh G; Balakumar P; Stockbridge N
Cell Signal; 2012 Aug; 24(8):1583-91. PubMed ID: 22522051
[TBL] [Abstract][Full Text] [Related]
37. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
38. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
39. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice.
Pöss J; Werner C; Lorenz D; Gensch C; Böhm M; Laufs U
Basic Res Cardiol; 2010 Nov; 105(6):725-35. PubMed ID: 20857126
[TBL] [Abstract][Full Text] [Related]
40. Antihypertensive therapy with aliskiren.
Luft FC; Weinberger MH
Kidney Int; 2008 Mar; 73(6):679-83. PubMed ID: 18160962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
